Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.51
+0.11 (1.72%)
Aug 13, 2025, 4:00 PM - Market closed
Allakos Employees
Evolus had 332 employees as of December 31, 2024. The number of employees increased by 59 or 21.61% compared to the previous year.
Employees
332
Change (1Y)
59
Growth (1Y)
21.61%
Revenue / Employee
$837,172
Profits / Employee
-$186,732
Market Cap
421.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 332 | 59 | 21.61% |
| Dec 31, 2023 | 273 | 58 | 26.98% |
| Dec 31, 2022 | 215 | 48 | 28.74% |
| Dec 31, 2021 | 167 | 48 | 40.34% |
| Dec 31, 2020 | 119 | -116 | -49.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EOLS News
- 5 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 13 days ago - Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins - Business Wire
- 22 days ago - Evolus to Report Second Quarter Financial Results on August 5, 2025 - Business Wire
- 23 days ago - Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings - Seeking Alpha
- 5 weeks ago - Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Business Wire
- 2 months ago - Evolysse™ Recognized in 2025 Shape Skin Awards - Business Wire